Abstract
Chemotherapy plus anti-EGFR therapy is the standard first-line treatment in RAS wild-type (wt) metastatic colorectal cancer (mCRC). The utility of ctDNA sequencing (liquid biopsy) to assess early molecular response to chemotherapy plus anti-EGFR therapy before radiological progression is yet to be determined, and should integrate information on changes in total tumor burden and early emergence of resistant sub-clones.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
